key: cord-0730373-ahfqcj97
authors: Vogel, E.; Kocher, K.; Priller, A.; Cheng, C.-C.; Steininger, P.; Liao, B.-H.; Koerber, N.; Willmann, A.; Irrgang, P.; Held, J.; Moosmann, C.; Schmidt, V.; Beileike, S.; Wytopil, M.; Heringer, S.; Bauer, T.; Brockhoff, R.; Jeske, S.; Mijocevic, H.; Christa, C.; Salmanton-Garcia, J.; Tinnefeld, K.; Bogdan, C.; Yazici, S.; Knolle, P.; Cornely, O. A.; Ueberla, K.; Protze, U.; Schober, K.; Tenbusch, M.
title: Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
date: 2022-03-27
journal: nan
DOI: 10.1101/2022.03.23.22272771
sha: 91ce2156cea3788a804336fc7c91bddf53179844
doc_id: 730373
cord_uid: ahfqcj97

Vaccines are the most important means to overcome the SARS-CoV-2 pandemic. They induce specific antibody and T-cell responses but it remains open how well vaccine-induced immunity is preserved over time following homologous and heterologous immunization regimens. Here, we compared the dynamics of humoral and cellular immune responses up to 5 months after homologous or heterologous vaccination with either ChAdOx1-nCoV-19 (ChAd) or BNT162b2 (BNT) or both. Antibody responses significantly waned after vaccination, irrespective of the regimen. The capacity to neutralize SARS-CoV-2 - including variants of concern such as Delta or Omicron - was superior after heterologous compared to homologous BNT vaccination, both of which resulted in longer-lasting humoral immunity than homologous ChAd immunization. T-cell responses showed less waning irrespective of the vaccination regimen. These findings demonstrate that heterologous vaccination with ChAd and BNT is a potent approach to induce long-term humoral and cellular immune protection.

The widespread use of safe and effective vaccines is essential for overcoming the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. As of today, billions of doses of Coronavirus Disease 19 vaccines, based on adenoviral vectors or mRNA, have been administered worldwide. In very rare cases, the administration of the adenoviral vector-based ChAdOx1-nCov-19 (ChAd) vaccine has been associated with the induction of a vaccine-induced thrombocytopenic thrombosis syndrome, particularly in young women 1 . Consequently, the vaccination authorities of several countries recommended that persons under the age of 60 years who had received a primary dose of ChAd should receive an mRNA-based Covid-19 vaccine for the second immunization 2 .

We and others have previously shown that the heterologous combination of ChAd and mRNA vaccination results in a non-inferior or even superior humoral and cellular immune response compared to homologous mRNA or ChAd vaccination regimens [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .

While homologous ChAd vaccination elicited a strong T-cell response shortly after the second immunization, antibody responses were inferior to homologous or heterologous regimens with mRNA vaccines. Furthermore, in the case of homologous vaccination regimens, various studies have shown a decline in antibody and T-cell levels a few months after the second dose 13 . For heterologous vaccination regimens, however, long-term follow-up data on how long B-and T-cell immunity persists are limited 14, 15 . This particularly applies to the immune response against newly emerged SARS-CoV-2 variants of concern (VoC) such as the Delta or Omicron mutant 8 .

Currently, it therefore remains unclear how the heterologous combination of ChAd and mRNA vaccination compares to homologous mRNA or ChAd vaccination in terms of long-term maintenance of humoral and cellular immunity.

Here, we examined humoral and cellular immunity in up to 473 participants from three different study centers at different time points before, and up to 5 months after heterologous and homologous vaccination with mRNA with BNT162b2 (BNT) and

ChAd. While T-cell responses showed only modest contraction, significant waning of humoral immunity was observed over time in all three vaccination regimens. Compared to homologous vaccination with ChAd or BNT, the heterologous regimen generally resulted in more constant antibody responses both in terms of quantity and quality.

We compared humoral and cellular immune responses in 473 healthy individuals about 2 weeks ("early after #2") and 3.5 to 5 months ("late after #2") after heterologous or homologous vaccination with ChAd and BNT (Table 1) . Previously, we had reported limited data on antibody responses early after second vaccination 5 . In the present analysis, median time points for the "early after #2" and "late after #2" analyses were 13-15 and 98-158 days after second vaccination, respectively. Analyses were performed at the study centers in Munich (Munich and Cologne samples) and Erlangen (Erlangen samples) ( Table 1 ). The results are presented by study center for better comparability.

We first assessed the quantities of antibody levels by a surrogate neutralization assay (sVNT) (Fig. 1 ). This assay correlates well with a real virus neutralization assay not only for the EU-strain SARS-CoV-2 D614G virus, as previously described 5 , but also for the Delta VoC (Suppl. Fig. 1 ). Regardless of the vaccination schedule, we observed significant waning of antibody levels in almost all individuals at the late time point (Table 1) .

At the study center in Munich (Fig. 1A) , antibody neutralization capacity at the followup time point was significantly reduced compared to the time point early after second vaccination, but the remaining antibody levels were similar after ChAd-BNT (median = 234.65 AU/ml; n = 43) and BNT-BNT (median = 328.17 AU/ml; n = 46) vaccination. At an independent study center in Erlangen, these results were confirmed (Fig. 1B) .

Furthermore, additional analysis of samples from a homologous ChAd-ChAd vaccination scheme cohort showed that neutralizing antibody levels late after homologous ChAd-ChAd vaccination (median of 9.32 AU/ml; n = 53) were still significantly lower compared to homologous BNT-BNT (median = 31.74 AU/ml; n = 119) or heterologous ChAd-BNT (median = 41.72 AU/ml; n = 201) vaccination (Fig.   1B) . Thus, the heterologous ChAd-BNT vaccination regimen results in long-term neutralizing antibody levels against SARS-CoV-2 WT virus which are as high as after homologous BNT-BNT and higher than after homologous ChAd-ChAd immunization.

To investigate potential differences in serological responses between the different cohorts in more detail, we next applied a "real" virus infection neutralization assay (rVNT) for the most relevant SARS-CoV-2 VoC. At the Munich study center, neutralization of VoC B.1.617.2 (Delta) and B.1.1.529 (Omicron) was investigated using sera collected 2 weeks and 3.5 months after heterologous ChAd-BNT or homologous BNT-BNT vaccination ( Fig. 2A) Fig. 2A) .

To confirm these results, serum samples from the Erlangen study center collected at 4.5 to 5 months after second vaccination ("late after #2") were analyzed in the rVNT assay for the ability to neutralize the Delta variant. These analyses again additionally included a cohort of homologous ChAd-ChAd vaccinated participants. Late after ChAd-ChAd immunization, barely any neutralization capacity against Delta was detectable (median IC50 = 20; n = 21), which was significantly different from the ChAd-BNT and BNT-BNT cohorts. In contrast to the results obtained at the Munich study center, there was no significant difference in neutralization capacity against Delta between the ChAd-BNT (median IC50 = 107.8; n = 30) and BNT-BNT (median IC50 = 172; n = 30) group (Fig. 2B) . These findings were further confirmed using a pseudovirus neutralization assay (pVNT), although overall the neutralization titers were slightly lower than in the rVNT (Suppl. Fig. 2 ). Whether this is due to the later sampling time point, the lower numbers of participants, or another reason, cannot be clarified. The reduced capacity to recognize the spike (S) proteins of VoC in comparison to the S protein of the original Wuhan strain observed in the pVNT assay (Suppl. Fig. 2 ) was confirmed by a flow cytometric analysis using HEK293 cells expressing the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in corresponding S proteins in their natural conformation on the cell surface (Suppl. Figure 3 ). Overall, these results demonstrate that humoral immunity against VoC was reduced irrespective of the vaccination regimen, but that differences in antibody neutralization capacity between the immunization cohorts remained unchanged.

The neutralization capacity of antibodies depends not only on their quantity, but also on their quality 16 . We therefore next applied a modified quantitative anti-S ELISA to determine antibody avidity against the S1 domain of the SARS-CoV-2 WT spike antigen. To this end, we used samples of the sub-cohorts from the Omicron rVNT analysis (Fig. 3 ). 2 weeks after second vaccination we observed a higher avidity of antibodies in the heterologous ChAd-BNT (median = 57.96 %) compared to the homologous BNT-BNT (median = 30.86 %) cohort. This difference remained constant at follow-up (Fig. 3 ). Over time, there was a tentative increase in antibody avidity for both groups (BNT-BNT median = 49.49 %; ChAd-BNT median = 65.69 %) which was, however, not statistically significant (Fig. 3) . These results indicate that higher antibody avidity after heterologous ChAd-BNT compared to homologous BNT-BNT vaccination contributes to non-inferior neutralization capacity (Fig. 1 ).

Given the critical role of T lymphocytes in protection against SARS-CoV-2 infection, we next also characterized the T-cell response elicited by heterologous or homologous vaccination regimens. We acquired peripheral blood mononuclear cells (PBMCs) from vaccinated individuals at the two study centers and characterized CD4 and CD8 T-cell responses by IFN-γ enzyme-linked immunospot (ELISPOT), IFN-γ/IL-2 Fluorospot as well as intracellular cytokine staining followed by flow cytometry analysis (ICCS). To this end, PBMCs were stimulated overnight with two 15mer peptide pools covering the S1 and S2 domains of the full-length SARS-CoV-2 spike glycoprotein, respectively.

To evaluate the dynamics of spike-specific T cells, the frequency of antigen-reactive, IFN-γ-producing T cells was first longitudinally characterized within the ChAd-BNT in Munich (Fig. 4A ) and the BNT-BNT cohort in Erlangen (Fig. 4B ) early after first and second vaccination, as well as at the late follow-up time point. Limited T-cell responses to spike peptide stimulation were observed in some individuals already before All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2022. ;  vaccination (Fig. 4B) , which might result from cross-reactive clonotypes derived from exposure to common cold coronaviruses 17, 18 . Induction of spike-specific T cells was Having demonstrated that spike-reactive T cells were detectable at least 4 months after the second vaccination, we next examined the effect of different vaccination regimens on the quality of the T-cell response in more detail. We therefore quantified IFN-γ secreting, spike-specific T cells 5 to 6 months after vaccination with the different vaccine regimens in study participants at the Erlangen study center (Fig. 4C ). IFN-γ ELISPOT detected reactive T cells in almost all individuals of ChAd-BNT, BNT-BNT and ChAd-ChAd vaccination cohorts. After heterologous ChAd-BNT vaccination, S1reactive T cells were detected at higher frequencies compared to the homologous BNT-BNT vaccination cohort while there was no difference for S2-specific T cells and the other vaccination schemes. Thus, heterologous vaccination was at least as efficient as homologous vaccination in inducing spike-reactive T-cell responses that are stable over time (Fig. 4C) .

T-cell polyfunctionality is a hallmark of high-quality immunity and predictive of protective immune responses 19 peptide stimulation at all. This effect was most probably due to variable recognition of CD8 epitopes within the 15mer peptides that were used for antigenic stimulation.

Overall, the frequency of polyfunctional T cells quantified by ICS correlated with the frequency of spike-reactive T cells determined by IFN-γ ELISPOT, further validating the findings (Suppl. Fig. 5 ). Fluorospot assays further confirmed the induction of IL-2 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in and IFN-γ secreting polyfunctional T cells after primary immunization with ChAd and secondary immunization with BNT, as well as the persistence of a polyfunctional CD4dominated T-cell response at the level of primary vaccination throughout the entire observation period (Suppl. Figure 6 ). In summary, all vaccination regimens induce stable and polyfunctional T-cell responses.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We here analyzed the humoral and cellular immune response of 473 participants from three different study sites, 2 weeks and several months after homologous and heterologous ChAd and BNT vaccination. Overall, heterologous vaccination with ChAd followed by BNT induced equal or even superior humoral and cellular immune responses compared to homologous BNT-BNT or ChAd-ChAd vaccination.

We and others had previously reported enhanced neutralization capacity early after heterologous ChAd-BNT vaccination compared to homologous BNT-BNT-vaccination, both of which in turn induced clearly higher neutralizing antibody titers than a homologous ChAd vaccination regimen [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Apart from significant waning of neutralization capacity towards WT virus at late time points for all regimens, we here observed that differences in humoral immunity towards WT virus between ChAd-BNT and BNT-BNT vaccination vanished, while homologous ChAd-ChAd still showed reduced neutralization titers compared to the other two vaccination schemes.

In line with previous reports 16,20-30 , S-specific antibodies induced by the current vaccines encoding the S protein from the original Wuhan strain have significantly reduced neutralizing activity against the SARS-CoV-2 VoC Delta, and even less activity against Omicron. Of note, we here detect such loss of neutralization for all vaccination schedules. In terms of differences between the immunization regimens, ChAd-BNT and BNT-BNT groups showed higher neutralizing antibody response against VoCs than the ChAd-ChAd group, as observed for WT virus.

The relative binding capacity to the different spike variants might be also indicative for the degree of immune evasion by the different VoCs. Since neutralizing antibody levels directly correlate with the level of protection against infection 31 , vaccine efficacy (VE) against infection with VoCs also decreased dramatically over time [32] [33] [34] . Nevertheless, 3 to 6 months after the second vaccination, VE were reported to be comparable for BNT-BNT and ChAd-BNT, but lower for ChAd-ChAd schedules 35, 36 .

Antibody quality might be even more important than the mere quantity for potent vaccine responses, as demonstrated by the high avidity of anti-spike antibodies after a third exposition 16 . In our study, antibody avidity increased slightly from the early to the late time point for both the ChAd-BNT and the BNT-BNT cohort, which might indicate ongoing B-cell maturation. It has been reported that this process could last up to 6 months in recipients of homologous mRNA vaccines or convalescent patients, while comparable data on heterologous vaccinations are missing [37] [38] [39] [40] [41] . A higher avidity All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Depending on the readout, the heterologous vaccination regimen was consistently non-inferior and sometimes statistically significantly superior to the homologous BNT immunization. It has already been shown that a priming dose of ChAd induces a stronger T-cell response compared to a primary immunization with BNT, which was however no longer the case after a secondary BNT immunization 53 . Nevertheless, this could still indicate that the overall superiority of humoral and cellular immunogenicity through the heterologous vaccination regimen results from a more potent primary immune response. For example, strong CD4 T-cell responses induced by primary ChAd vaccination may also explain why serological antibody responses after heterologous ChAd-BNT vaccination are more prominent than after homologous BNT-BNT vaccination 53 .

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Polyfunctionality as a predictor of an effective T-cell immune response was demonstrated for persisting T cells after all vaccination regimens 19 . Especially polyfunctional CD4 T cells were well maintained 4 months after the second vaccination. For CD8 T cells this was less clear, most probably owing to variable recognition of (shorter) CD8 epitopes within the 15mer peptides that were used for antigenic stimulation. Overall, our data show that heterologous vaccination is at least as capable as homologous vaccination regimens in inducing long-term maintenance of polyfunctional spike-specific T cells, which are likely to convey protective immunity.

In summary, these data document at least non-inferior humoral and cellular immunogenicity after heterologous ChAd-BNT vaccination compared to the respective homologous regimens. While waning of humoral immunity and reduced neutralization perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The study is a follow-up analysis of 473 homologously or heterologously vaccinated participants that were previously only assessed for the production of antibodies using sVNT 5 Therefore, all results exceeding this limit have been set to 800 AU/ml. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Binding strength of the SARS-Cov-2 IgG antibodies was determined by adaptation of the commercial IgG agile SARS-CoV-2 ELISA (Virion/Serion, Germany) using ammonium thiocyanate (NH4SCN) (Roth, Germany) as previously described 16, 54, 55 .

Serum samples were measured using the IgG agile SARS-CoV-2 ELISA and diluted to 100 U/mL according to the standard curve provided by the manufacturer to exclude an influence of variable antibody concentrations. Thereafter, serum samples were incubated in the plates pre-coated with Wuhan SARS-CoV-2-spike-ectodomain S1, S2 and BD recombinant antigens for 1h at 37°C in a humid chamber. After washing, antigen-antibody complexes were incubated in the presence of 1.0 M ammonium thiocyanate or PBS as control for 10 min at room temperature. After washing to remove antibodies bound with low avidity, the ELISA was completed according to the manufacturer's instructions. The relative avidity index was calculated as follows: IgG concentrations (NH4SCN) / IgG concentrations (PBS) x 100, and is given in percent.

Based on a previously established infection inhibition assay 16 After fixation, cells were washed with PBS and permeabilized with 0.5% saponin (Sigma-Aldrich, Germany). Blocking buffer, consisting of 0.1% saponin-10% goat serum (Sigma-Aldrich) in PBS, was added and incubated for one hour on fixed cells to avoid unspecific binding of antibodies. As a primary antibody, the SinoBiological anti-SARS-CoV-2-N T62 antibody (40143-T62) was used. The antibody was diluted with All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 1% FCS-PBS to 1:1500 ratio and 50µl were added in each well and incubated at room temperature for 2 hours. After washing, the second antibody was added. Goat antirabbit IgG2a-HRP antibody (EMD Millipore / order number 12-348) with 1% FCS-PBS was diluted to 1:4000 ratio. 50µl were added and incubated at room temperature for 1- 

Neutralization of the early D614G (WT) and the B1.617.2 variants was assessed with the help of spike-pseudotyped simian immunodeficiency virus particles as described before 57 . To produce pseudotyped reporter particles, HEK293T cells were transfected with the SIV-based self-inactivating vector encoding luciferase (pGAE-LucW), the SIVbased packaging plasmid (pAdSIV3), and the respective spike variant-encoding plasmid as described previously 58 .

For the assessment of pseudotype neutralization, HEK293T-ACE2 cells were seeded at 2x10 4 cells/well in a 96well flat bottom plate. 24 h later, 60 µl of serial dilutions of the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

PBMCs were isolated from citrate peripheral blood of vaccinated individuals by density gradient centrifugation using Biocoll ® separating solution, density 1.077 g/ml (Bio&Sell) and frozen in heat-inactivated FCS + 10% DMSO (Sigma-Aldrich) for liquid nitrogen storage. Thawed PBMCs were cultured in complete RPMI medium (RPMI 1640 medium (Thermo Fisher) supplemented with 10% heat-inactivated FCS, 1 mM ß-Mercaptoethanol, 1 mg/ml gentamicin, 23.83 g/l HEPES, 4.0 g/l L-glutamine, and 2000 U/ml penicillin-streptomycin) at 37°C and 5% CO2.

Cryopreserved PBMCs were thawed and rested overnight at 1x10 6 

Cryopreserved PBMCs were thawed and rested overnight at 2x10 6 cells/ml in complete RPMI medium. Human IFN-γ/IL-2 Fluorospot assays (CTL Europe, Germany) were performed according to the manufacturer's instructions. One day before the Fluorospot assays were performed, the plates were activated by adding 70% ethanol for less than (visualizes IFN-γ) and anti-Hapten2 CTL-Red™ (visualizes IL-2) was added for one hour. The staining procedure was stopped by washing the plate. After drying the plates for 24h on paper towels on bench top, Fluorospot plates were scanned and analyzed using an automated reader system (ImmunoSpot Ultimate UV Image analyzer/ImmunoSpot 7.0.17.0 Professional DC Software, CTL Europe GmbH, Germany). Positive reactivity to experimental stimulatory agents was given when the spot count in antigen-stimulated cells was greater than twice the spot count in unstimulated (background) wells.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Statistics as well as figures were created with PRISM GraphPad 9.3.1.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2022. ; ((A) (B) ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and n.s. indicates not significant. A detailed description of the data can be found in Supplemental Table for Figure 2A "early after #1": 10 days after first BNT vaccination, n=21. "early after #2": 10 days after second BNT vaccination, n=17. "late after 2#": 4 months after second BNT vaccination, n=13. The time points "before", "early after #1", and "early after #2" refer to a separate cohort of vaccinees that was included for contextualization. (C) Cohort comparison of spike-specific T cells after stimulation with SARS-CoV-2 spike peptide pools S1 and S2, in dilution of solvent (Neg. ctrl.), or with PMA/ionomycin (Pos. ctrl.). Vaccinees of Erlangen study center 4 months after second vaccination (late after #2).

Representative data (left) and quantification of IFN-γ SFU for all donors of indicated All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2022. ;  vaccination cohorts (right) are displayed. (D)-(F) Flow cytometric analyses of polyfunctional spike-specific T cells after stimulation with SARS-CoV-2 spike peptide pools S1 and S2, in dilution of solvent (Neg. ctrl.), or with PMA/ionomycin (Pos. ctrl.).

Vaccinees of Erlangen study center 4 month after second vaccination (late after #2). (B)). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and n.s. indicates not significant.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 27, 2022. ;  lost to follow-up, n 4 7 0 0 0 MUC, Munich; CGN, Cologne; ERL, Erlangen; IQR: interquartile range Table 1 : Detailed representation of different study cohorts, separated by study center.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Figure 3 All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Beschluss der STIKO zur 5. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med

Heterologous ChAdOx1 nCoV-19 and BNT162b2 primeboost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Heterologous ChAdOx1 nCoV-19 and mRNA-1273

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

T-cell quality in memory and protection: implications for vaccine design

Increased Potency and Breadth of SARS-CoV-2

Neutralizing Antibodies After a Third mRNA Vaccine Dose

Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. The Lancet Infectious Diseases

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Neutralizing antibodies against the SARS-CoV-2

Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Neutralizing antibodies against the SARS-CoV-2

Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Germinal centre-driven maturation of B cell response to mRNA vaccination

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

mRNA Vaccine-Elicited SARS-CoV-2-Specific T cells Persist at 6 Months and Recognize the Delta Variant

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

The T cell immune response against SARS-CoV-2

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

Divergent SARS CoV-2 Omicron-reactive T-and B cell responses in COVID-19 vaccine recipients

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination

Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate

A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid

Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2

Seasonal Betacoronavirus Antibodies' Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

The study was funded by the German Centre for Infection Research (DZIF), the European Union's "Horizon 2020 Research and Innovation Programme" under grant